ASX-listed health and wellness company Bioxyne has unveiled a new online healthcare service, BLS Clinics, developed in partnership with technology provider InstantScripts.
The launch follows Bioxyne's acquisition of Breathe Life Sciences (BLS), which was completed in May, with BLS co-founder and CEO Sam Watson and COO Jason Hine both joining the board at that time.
The deal saw Bioxyne acquire 100% of BLS via a share transaction, with former BLS shareholders now holding a 66% stake in the combined company.
BLS Clinics operates as an online telehealth platform focused on plant-based healthcare consultations for patients managing chronic health conditions.
Watson said: "BLS Clinics allows patients to access alternative medicines to treat chronic health conditions through a delivery system that is safe and regulated.
"Our mission is to democratise healthcare and pharma to be a global leader in the manufacture and supply of novel medicines, healthcare and health-tech solutions… and to empower patients with advanced technology for screening, access, suitability, and treatment."
BLS holds Australian licences to import, export, wholesale and manufacture Schedule 3, 4 and 8 medicines including medicinal cannabis and ketamine. It has operations in Australia, the UK, Europe, Japan, Southeast Asia, and the US.
Its international portfolio includes CBD and mushroom brand Dr Watson, sold in the UK and Japan. The company also supplies cannabis-derived raw materials and active pharmaceutical ingredients to markets around the world.
